United States Biotechnology & Medical Research

Omeros Corp (OMER)

Track

Omeros Corp experienced recent insider trading activity involving director Thomas Cable, who executed planned sales totaling approximately $176,739 in late May 2026. These divestments occurred shortly after the company released its latest earnings report, which showed a significant earnings per share beat. The stock price has declined 7.7% over the past ninety days.
Ticker: OMER Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Omeros Corp. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 22 May 2026
Value US$276,366.87 | Price 105.93 | Shares 6,644 (+33.5%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-27 2026-05-22 PlS Planned sale
3.2
Cable Thomas J.
Non-Executive Director
6,644 +33.5%
105.93
US$276,367 		6,644 +33.5% 105.93 US$276,367
2026-05-22 2026-05-22 PrS Proposed sale
3.2
Thomas Cable

Director

Non-Executive Director
5,292
14.50
US$4,331,834 		5,292 14.50 US$4,331,834
2026-01-14 2026-01-13 S Sale
2.5
Borges David J.

VP, Finance & CAO

Officer
4,124 -45.7%
35.20
US$3,878,789 		4,124 -45.7% 35.20 US$3,878,789
2026-01-13 2026-01-13 PrS Proposed sale
2.5
DAVID J BORGES

Officer

Officer
30,000
12.31
US$369,315 		30,000 12.31 US$369,315
2026-01-14 2026-01-12 S Sale
2.5
Borges David J.

VP, Finance & CAO

Officer
30,000 -100.0%
12.72
US$381,600 		30,000 -100.0% 12.72 US$381,600
2026-01-12 2026-01-12 PrS Proposed sale
2.5
DAVID J BORGES

Officer

Officer
30,000
12.72
US$381,600 		30,000 12.72 US$381,600
2023-11-21 2023-11-17 B Purchase
3.4
Demopulos Gregory A MD

Chairman, CEO & President

Officer
15,000 +13.8%
1.68
US$25,200 		15,000 +13.8% 1.68 US$25,200
2023-11-17 2023-11-15 B Purchase
3.4
Demopulos Peter A MD
Non-Executive Director
10,000 +5.0%
1.53
US$15,300 		10,000 +5.0% 1.53 US$15,300
2023-09-20 2023-09-20 PrS Proposed sale
3.7
KURT ZUMWALT

Officer

Officer
7,500
3.02
US$22,672 		7,500 3.02 US$22,672
2023-05-23 2023-05-22 S Sale
3.2
Cable Thomas J.
Non-Executive Director
5,000 -12.5%
6.53
US$32,650 		5,000 -12.5% 6.53 US$32,650
2023-05-23 2023-05-22 S Sale
2.7
HANISH ARNOLD C
Non-Executive Director
5,000 -100.0%
6.46
US$32,300 		5,000 -100.0% 6.46 US$32,300
2023-05-22 2023-05-22 PrS Proposed sale
3.2
THOMAS J CABLE

Director

Non-Executive Director
5,000
6.53
US$32,669 		5,000 6.53 US$32,669
2023-05-22 2023-05-22 PrS Proposed sale
2.7
ARNOLD HANISH

Director

Non-Executive Director
5,000
6.46
US$32,294 		5,000 6.46 US$32,294
2021-06-17 2021-06-17 PlS Planned sale
3.4
Demopulos Gregory A MD

CHAIRMAN, CEO & PRESIDENT

Executive Director
36,857 -1.8%
14.90
US$549,169 		36,857 -1.8% 14.90 US$549,169
2021-06-17 2021-06-15 PlS Planned sale
3.4
Demopulos Gregory A MD

CHAIRMAN, CEO & PRESIDENT

Executive Director
36,856 -1.8%
15.02
US$553,577 		36,856 -1.8% 15.02 US$553,577
2021-04-08 2021-04-08 PlS Planned sale
3.4
Demopulos Gregory A MD

CHAIRMAN, CEO & PRESIDENT

Executive Director
35,206 -1.7%
17.76
US$625,259 		35,206 -1.7% 17.76 US$625,259
2021-04-08 2021-04-07 PlS Planned sale
3.4
Demopulos Gregory A MD

CHAIRMAN, CEO & PRESIDENT

Executive Director
37,407 -1.8%
17.91
US$669,959 		37,407 -1.8% 17.91 US$669,959
2021-02-23 2021-02-22 PlS Planned sale
JACOBSEN MICHAEL A

VP FINANCE AND CAO

Officer
8,100 -36.7%
23.28
US$188,568 		8,100 -36.7% 23.28 US$188,568
2021-02-23 2021-02-19 PlS Planned sale
JACOBSEN MICHAEL A

VP FINANCE AND CAO

Officer
10,000 -41.7%
22.64
US$226,400 		10,000 -41.7% 22.64 US$226,400
2021-02-12 2021-02-10 PlS Planned sale
JACOBSEN MICHAEL A

VP FINANCE AND CAO

Officer
1,900 -11.9%
22.49
US$42,731 		1,900 -11.9% 22.49 US$42,731
2021-01-21 2021-01-19 PlS Planned sale
JACOBSEN MICHAEL A

VP FINANCE AND CAO

Officer
9,500 -70.4%
19.95
US$189,525 		9,500 -70.4% 19.95 US$189,525
2021-01-15 2021-01-13 PlS Planned sale
3.2
Cable Thomas J.
Non-Executive Director
5,000 -12.5%
16.97
US$84,850 		5,000 -12.5% 16.97 US$84,850
2020-05-15 2020-05-13 PlS Planned sale
3.2
Cable Thomas J.
Non-Executive Director
5,000 -12.5%
14.40
US$71,998 		5,000 -12.5% 14.40 US$71,998
2019-12-05 2019-12-03 PlS Planned sale
3.2
Cable Thomas J.
Non-Executive Director
10,000 -22.2%
14.41
US$144,148 		10,000 -22.2% 14.41 US$144,148
2019-10-16 2019-10-14 PlS Planned sale
3.2
Cable Thomas J.
5,000 -12.5%
15.12
US$75,590 		5,000 -12.5% 15.12 US$75,590
2018-08-31 2018-08-31 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
5,337 -2.7%
25.93
US$138,376 		5,337 -2.7% 25.93 US$138,376
2018-08-31 2018-08-31 PlS Planned sale
Kelbon Marcia S.

VP Patent and General Counsel

Officer
2,192 -1.1%
25.31
US$55,469 		2,192 -1.1% 25.31 US$55,469
2018-08-31 2018-08-30 PlS Planned sale
Kelbon Marcia S.

VP Patent and General Counsel

Officer
35,000 -15.4%
24.45
US$855,750 		35,000 -15.4% 24.45 US$855,750
2018-07-30 2018-07-27 PlS Planned sale
Kelbon Marcia S.

VP Patent and General Counsel

Officer
5,723 -2.9%
21.73
US$124,357 		5,723 -2.9% 21.73 US$124,357
2018-07-30 2018-07-26 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
35,000 -15.9%
21.53
US$753,686 		35,000 -15.9% 21.53 US$753,686
2018-07-13 2018-07-12 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
4,277 -2.3%
21.48
US$91,886 		4,277 -2.3% 21.48 US$91,886
2018-05-16 2018-05-15 PlS Planned sale JACOBSEN MICHAEL A

VP Finance and CAO

Officer
12,812 -60.1%
24.95
US$319,659 		12,812 -60.1% 24.95 US$319,659
2018-05-16 2018-05-14 PlS Planned sale
JACOBSEN MICHAEL A

VP Finance and CAO

Officer
10,980 -56.4%
22.45
US$246,501 		10,980 -56.4% 22.45 US$246,501
2018-01-05 2018-01-03 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
62,528 -26.1%
21.45
US$1,341,226 		62,528 -26.1% 21.45 US$1,341,226
2018-01-05 2018-01-03 PlS Planned sale
JACOBSEN MICHAEL A

VP Finance and CAO

Officer
1,020 -12.0%
22.45
US$22,899 		1,020 -12.0% 22.45 US$22,899
2017-06-16 2017-06-16 PlS Planned sale JACOBSEN MICHAEL A

VP Finance and CAO
12,000 -61.5%
24.95
US$299,400 		12,000 -61.5% 24.95 US$299,400
2017-06-15 2017-06-15 PlS Planned sale JACOBSEN MICHAEL A

VP Finance and CAO
12,000 -68.6%
22.45
US$269,400 		12,000 -68.6% 22.45 US$269,400
2017-06-15 2017-06-14 PlS Planned sale JACOBSEN MICHAEL A

VP Finance and CAO
9,350 -72.8%
19.95
US$186,532 		9,350 -72.8% 19.95 US$186,532
2017-06-15 2017-06-13 PlS Planned sale JACOBSEN MICHAEL A

VP Finance and CAO
2,650 -100.0%
19.95
US$52,868 		2,650 -100.0% 19.95 US$52,868
2017-04-14 2017-04-12 PlS Planned sale Cable Thomas J.
3,000 -7.0%
16.49
US$49,474 		3,000 -7.0% 16.49 US$49,474
2016-12-16 2016-12-14 PlS Planned sale
3.2
Cable Thomas J.
Non-Executive Director
3,000 -6.5%
10.21
US$30,642 		3,000 -6.5% 10.21 US$30,642
2016-12-07 2016-12-07 PlS Planned sale Demopulos Gregory A MD

Chairman, CEO & President

Executive Director
102,044 -5.1%
10.48
US$1,069,033 		102,044 -5.1% 10.48 US$1,069,033
2016-12-07 2016-12-06 PlS Planned sale Demopulos Gregory A MD

Chairman, CEO & President

Executive Director
102,040 -5.1%
10.80
US$1,101,808 		102,040 -5.1% 10.80 US$1,101,808
2016-12-07 2016-12-05 PlS Planned sale Demopulos Gregory A MD

Chairman, CEO & President

Executive Director
102,040 -5.1%
10.71
US$1,092,644 		102,040 -5.1% 10.71 US$1,092,644
2016-12-02 2016-12-02 PlS Planned sale Demopulos Gregory A MD

Chairman, CEO & President

Executive Director
102,040 -5.7%
11.00
US$1,122,593 		102,040 -5.7% 11.00 US$1,122,593
2016-12-02 2016-12-01 PlS Planned sale Demopulos Gregory A MD

Chairman, CEO & President

Executive Director
999 -0.1%
12.32
US$12,303 		999 -0.1% 12.32 US$12,303
2016-12-02 2016-12-01 PlS Planned sale Demopulos Gregory A MD

Chairman, CEO & President

Executive Director
105,522 -5.8%
11.56
US$1,219,760 		105,522 -5.8% 11.56 US$1,219,760
2016-12-02 2016-11-30 PlS Planned sale Demopulos Gregory A MD

Chairman, CEO & President

Executive Director
97,559 -5.4%
12.21
US$1,191,478 		97,559 -5.4% 12.21 US$1,191,478
2016-09-16 2016-09-15 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
16,000 -8.9%
10.91
US$174,578 		16,000 -8.9% 10.91 US$174,578
2016-08-16 2016-08-15 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
15,900 -8.9%
11.56
US$183,826 		15,900 -8.9% 11.56 US$183,826
2016-08-16 2016-08-12 PlS Planned sale Cable Thomas J. Non-Executive Director
3,000 -6.1%
11.52
US$34,557 		3,000 -6.1% 11.52 US$34,557
2016-07-15 2016-07-15 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
15,900 -8.9%
11.50
US$182,804 		15,900 -8.9% 11.50 US$182,804
2016-06-17 2016-06-15 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
15,900 -8.9%
11.42
US$181,503 		15,900 -8.9% 11.42 US$181,503
2016-05-18 2016-05-16 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
15,900 -8.9%
9.94
US$158,057 		15,900 -8.9% 9.94 US$158,057
2016-04-15 2016-04-15 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
15,900 -8.9%
15.18
US$241,392 		15,900 -8.9% 15.18 US$241,392
2016-03-25 2016-03-24 PlS Planned sale Cable Thomas J. Non-Executive Director
400 -0.8%
15.22
US$6,089 		400 -0.8% 15.22 US$6,089
2016-03-25 2016-03-24 PlS Planned sale
3.2
Cable Thomas J.
Non-Executive Director
1,600 -3.1%
14.71
US$23,538 		1,600 -3.1% 14.71 US$23,538
2016-03-17 2016-03-15 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
15,900 -9.7%
15.12
US$240,414 		15,900 -9.7% 15.12 US$240,414
2016-03-10 2016-03-08 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
31,800 -17.6%
15.03
US$478,005 		31,800 -17.6% 15.03 US$478,005
2015-12-22 2015-12-22 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
746 -0.5%
15.00
US$11,190 		746 -0.5% 15.00 US$11,190
2015-12-22 2015-12-18 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
15,154 -10.4%
15.00
US$227,310 		15,154 -10.4% 15.00 US$227,310
2015-11-25 2015-11-23 PlS Planned sale Kelbon Marcia S.

VP Patent and General Counsel

Officer
15,900 -10.8%
15.00
US$238,500 		15,900 -10.8% 15.00 US$238,500
2015-09-08 2015-09-04 B Purchase Demopulos Peter A MD Non-Executive Director
3,962 +2.2%
12.68
US$50,238 		3,962 +2.2% 12.68 US$50,238
2015-03-26 2015-03-24 PlS Planned sale
3.2
Cable Thomas J.
Non-Executive Director
210 -0.4%
25.07
US$5,264 		210 -0.4% 25.07 US$5,264
2014-06-24 2014-06-24 B Purchase Demopulos Peter A MD Non-Executive Director
6,153 +3.5%
16.20
US$99,704 		6,153 +3.5% 16.20 US$99,704
2014-06-04 2014-06-02 PlS Planned sale Cable Thomas J. Non-Executive Director
100 -0.2%
12.34
US$1,234 		100 -0.2% 12.34 US$1,234
2013-01-04 2013-01-04 B Purchase Aspiri Ray Non-Executive Director
40,000 +27.2%
5.72
US$228,800 		40,000 +27.2% 5.72 US$228,800
2013-01-03 2013-01-03 B Purchase Demopulos Peter A MD Non-Executive Director
9,345 +5.6%
5.42
US$50,650 		9,345 +5.6% 5.42 US$50,650
2013-01-03 2013-01-03 B Purchase
2.7
HANISH ARNOLD C
Non-Executive Director
2,000 +500.0%
5.58
US$11,160 		2,000 +500.0% 5.58 US$11,160
2012-09-28 2012-09-26 PlS Planned sale
3.2
Cable Thomas J.
Non-Executive Director
5,000 -5.2%
9.60
US$48,000 		5,000 -5.2% 9.60 US$48,000
2012-06-29 2012-06-27 B Purchase Demopulos Peter A MD Non-Executive Director
14,635 +9.7%
10.25
US$150,009 		14,635 +9.7% 10.25 US$150,009
2011-05-16 2011-05-16 B Purchase Demopulos Peter A MD Non-Executive Director
21,000 +17.7%
4.95
US$103,963 		21,000 +17.7% 4.95 US$103,963
2011-05-16 2011-05-13 B Purchase Demopulos Peter A MD Non-Executive Director
19,000 +19.1%
5.00
US$94,918 		19,000 +19.1% 5.00 US$94,918
Explore more

More insider trading research around Omeros Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America